Ashurst advised LSE listed PE firm ICG on the investment in Alfa Medicus 

Global law firm Ashurst represented Intermediate Capital Group (“ICG”), LSE listed global alternative asset manager, on its investment into Alfa Medicus Pte. Ltd. (the “Company”) alongside Dr Lim Beng Hai (“Dr Lim”), the founder of the Company, and a consortium of healthcare professionals.

Alfa Medicus is a leading private day surgery operator in Singapore, complete with a synergistic platform of day surgery centres, diagnostic imaging and specialist clinics.

The Company has applied the proceeds of ICG’s investment towards acquiring 14 healthcare companies which operates under brand names including Novena Surgery, Aptus Surgery, Novaptus Surgery, OHM and CHARMS

Ashurst’s Southeast Asia head of M&A Tao Koon Chiam commented, “We are pleased to support ICG, a key client of our firm, in this significant investment in Asia’s healthcare landscape.”

The transaction was led by Ashurst ADTLaw director Tao Koon Chiam, supported by Ashurst ADTLaw director Xiaozheng Ko, and Stefanie Loh and Charissa Loi.

/Public Release.